Abstract
Administration of opioids for analgesia may produce pruritus. It was believed, that this effect is mediated centrally by activation of μ-opioid receptors (MOR). However, recent data suggested that opioids may also mediate pruritus directly in the skin. A number of skin cell types, including keratinocytes, dermal mast cells, fibroblasts or macrophages, were shown to express both MOR as well as other opioid receptors. It was demonstrated, that the activation of MOR in the skin elicited pruritus, while activation of cutaneous µ- opioid receptors had anti-pruritic effect. Moreover, activation of opioid receptors in the skin modulated not only pruritus, but also inflammatory response. Taking these observations into consideration it could be suggested, that substances acting solely on peripheral opioid receptors could be potent anti-pruritic or even anti-inflammatory drugs, but devoided of typical side effects related to the activation of central opioid system.
Keywords: Anti-pruritic agents, itch, opioids, peripheral opioid system, skin, analgesia, pruritus, μ-opioid receptors (MOR), keratinocytes, anti-inflammatory drugs.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies
Volume: 18 Issue: 37
Author(s): Adam Reich and Jacek C. Szepietowski
Affiliation:
Keywords: Anti-pruritic agents, itch, opioids, peripheral opioid system, skin, analgesia, pruritus, μ-opioid receptors (MOR), keratinocytes, anti-inflammatory drugs.
Abstract: Administration of opioids for analgesia may produce pruritus. It was believed, that this effect is mediated centrally by activation of μ-opioid receptors (MOR). However, recent data suggested that opioids may also mediate pruritus directly in the skin. A number of skin cell types, including keratinocytes, dermal mast cells, fibroblasts or macrophages, were shown to express both MOR as well as other opioid receptors. It was demonstrated, that the activation of MOR in the skin elicited pruritus, while activation of cutaneous µ- opioid receptors had anti-pruritic effect. Moreover, activation of opioid receptors in the skin modulated not only pruritus, but also inflammatory response. Taking these observations into consideration it could be suggested, that substances acting solely on peripheral opioid receptors could be potent anti-pruritic or even anti-inflammatory drugs, but devoided of typical side effects related to the activation of central opioid system.
Export Options
About this article
Cite this article as:
Reich Adam and C. Szepietowski Jacek, Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies, Current Pharmaceutical Design 2012; 18(37) . https://dx.doi.org/10.2174/138161212803582405
DOI https://dx.doi.org/10.2174/138161212803582405 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design Base Excision Repair: Contribution to Tumorigenesis and Target in Anticancer Treatment Paradigms
Current Medicinal Chemistry EGFR Intron Recombination in Human Gliomas: Inappropriate Diversion of V(D)J Recombination?
Current Genomics GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy
Current Clinical Pharmacology Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Dietary Polyphenols for Prostate Cancer Therapy
Current Bioactive Compounds Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology Melatonin: Pharmacology, Functions and Therapeutic Benefits
Current Neuropharmacology Estrogens and Progression of Diabetic Kidney Damage
Current Diabetes Reviews Progress Towards Clinically Useful Aldosterone Synthase Inhibitors
Current Topics in Medicinal Chemistry Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Editorial (Thematic Issue: Endoplasmic Reticulum Stress and Mitochondrial Dysfunction in Diseases: Molecular Targets)
Current Pharmaceutical Design Effects of Quercetin against Mycotoxin Induced Cytotoxicity: A Mini- Review
Current Nutrition & Food Science Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Cellular and Molecular Effects of Macrolides on Leukocyte Function
Current Pharmaceutical Design Thrombospondins as Anti-Angiogenic Therapeutic Agents
Current Pharmaceutical Design Restoring p53 Function in Cancer: Novel Therapeutic Approaches for Applying the Brakes to Tumorigenesis
Recent Patents on Anti-Cancer Drug Discovery Dynamic Simulations of Pathways Downstream of ERBB-Family, Including Mutations and Treatments: Concordance with Experimental Results
Current Cancer Drug Targets Isovitexin Inhibits Stemness and Induces Apoptosis in Hepatocellular Carcinoma SK-Hep-1 Spheroids by Upregulating miR-34a Expression
Anti-Cancer Agents in Medicinal Chemistry Activin Receptor-Like Kinases: Structure, Function and Clinical Implications
Endocrine, Metabolic & Immune Disorders - Drug Targets